Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

NCT06587451 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
52
Enrollment
INDUSTRY
Sponsor class

Stopped In light of the evolving regulatory landscape and growing indications that major Health Authorities will move towards a streamlined clinical development, Sandoz took a strategic decision and is winding down its CJPB898A12301 clinical study.

Conditions

Interventions

Sponsor

Sandoz